Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 15/20 | 1.00 |
| ▸ | NQO2 | P16083 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409541 | 0.87 | ALDH1A1 (0.80) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL4756887 | 0.87 | ALDH1A1 (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31543713 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL8946916 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL5439854 | 0.86 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31530479 | 0.86 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31530480 | 0.86 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL13436444 | 0.86 | MTNR1A (0.88) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL3221458 | 0.85 | KDM4E (0.84) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL1311849 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480467-B | Synthesis process of radioactive tracer 2-iodine melatonin | 河北维达康生物科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-113480467-A | Synthesis process of radioactive tracer 2-iodine melatonin | 河北维达康生物科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-108699056-A | Method for treating atopic dermatitis | 江伯伦 | 2018-10-23 | — | — | CN | claimed |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | CHIANG BOR LUEN (TW) | 2018-10-18 | — | — | US | claimed |
| WO-2017107567-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | CHIANG BOR-LUEN (CN) | 2017-06-29 | — | — | WO | claimed |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | claimed |
| EP-3119406-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | Carmel-Haifa University Economic Corporation Ltd (IL) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140799-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD (IL) | 2015-09-24 | — | — | WO | claimed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | claimed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | claimed |
| US-6403631-B1 | ADMINISTERING MELATONIN OR ANALOG TO A HORSE OR SHEEP DURING FOLLICULAR DEVELOPMENT | EQUITECH LABORATORIES, INC. | 2002-06-11 | — | — | US | claimed |
| EP-0641565-B1 | Contraceptive and menstrual cycle controlling drug having oncostatic properties | I F L O S A S DI GIORGIO E ALD (IT) | 2000-03-15 | — | — | EP | claimed |
| EP-0513702-B1 | Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication | I F L O ISTITUTO FARMACOLOGICO (IT) | 1996-09-18 | — | — | EP | claimed |
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | claimed |
| EP-0483077-B1 | A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas. | I F L O S A S DI GIORGIO E ALD (IT) | 1995-12-06 | — | — | EP | claimed |
| US-5430029-A | Pharmaceutical compositions active in the therapy of sleep disorders | IFLO-ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. DI GIORGIO E ALD. LAGUZZI (IT) | 1995-07-04 | — | — | US | claimed |
| EP-0641565-A1 | Contraceptive and menstrual cycle controlling drug having oncostatic properties | I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi (IT) | 1995-03-08 | — | — | EP | claimed |
| US-5272141-A | Contraceptive and menstrual cycle controlling drug having oncostatic therapeutic properties for treatment of mammary tumors and melanomas, and method therefor | FRASCHINI FRANCO (IT) | 1993-12-21 | — | — | US | claimed |
| EP-0513702-A2 | Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication | I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. (IT) | 1992-11-19 | — | — | EP | claimed |
| EP-0483077-A2 | A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas. | I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi (IT) | 1992-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | MTNR1A 51/4885MTNR1B 70/4885NQO2 2232/4885 |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | MTNR1A, MTNR1B, TSLP | MTNR1A 1/4885MTNR1B 2/4885NQO2 2094/4885 |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, DHFR | MTNR1A 401/4885MTNR1B 547/4885NQO2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.